

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4307975

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MEI-YIN LEE	01/02/2013
RECEIVING PARTY DATA	
Name:	Glaxo Group Limited
Street Address:	Berkeley Avenue
City:	Greenford, Middlesex
State/Country:	UNITED KINGDOM
Postal Code:	UB6 0NN
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15254160
CORRESPONDENCE DATA	
Fax Number:	(610)270-5253
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	610-270-5019
Email:	US_CIPKOP@GSK.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	CIP UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	PU65008C2
NAME OF SUBMITTER:	SANDRA MANTON
SIGNATURE:	/SandraManton/
DATE SIGNED:	03/08/2017
Total Attachments: 3	
source=PU65008_assignment#page1.tif	
source=PU65008_assignment#page2.tif	
source=PU65008_assignment#page3.tif	

ASSIGNMENT

WHEREAS I/WE, **Mei-yin LEE** of Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY UK a citizen of the United Kingdom (hereinafter called "the inventor(s)") have invented or discovered **CRYSTAL FORM OF RILAPLADIB** (hereinafter called "the invention") for which a patent application No. 61/530104 was filed on 1 September 2011 in the United States of America and for which an international patent application PCT/EP2012/067027 was filed 31 August 2012 designating the United States of America.

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely **GLAXOSMITHKLINE SERVICES UNLIMITED** a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from **GLAXOSMITHKLINE SERVICES UNLIMITED** the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** have authorised and requested my/our making the application, and

WHEREAS **GLAXO GROUP LIMITED** a corporation organised and existing under and by virtue of the laws of the of England and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** the whole right, title and interest in and to the invention and the application in respect of the United States of America and all foreign countries in which this application is filed;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE SERVICES**

UNLIMITED of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXOSMITHKLINE SERVICES UNLIMITED**. **GLAXOSMITHKLINE SERVICES UNLIMITED** in turn hereby assigns and transfers to **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO GROUP LIMITED** its whole right, title and interest in and throughout the United States of America, **and in and throughout all foreign countries in which this application is filed**, in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America, **or in any foreign country in which this application is filed**, be issued to **GLAXO GROUP LIMITED**.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO GROUP LIMITED**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America, **and in any foreign country in which this application is filed**;

IN WITNESS whereof and with effect from 1 September 2011 the inventor(s) and Lorraine B. LING as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Mei-yin LEE

Date:

Meeyin

2 January 2013

SIGNED by Lorraine B. LING as the Attorney of each of GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED:

Lorraine B. Ling

Date: *7 January 2013*